Bone Alterations in Inflammatory Bowel Diseases

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2019 Aug 20

PMID 31423424

Citations 23

Authors

Dolores Sgambato

Francesca Gimigliano

Cristiana De Musis

Antimo Moretti

Giuseppe Toro

Emanuele Ferrante

Agnese Miranda

Domenico De Mauro

Lorenzo Romano

Giovanni Iolascon

Marco Romano

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel diseases (IBDs) are characterized by a multifactorial partially unknown etiology that involves genetic, immunological and environmental factors. Up to 50% of IBD patients experience at least one extraintestinal manifestation; among them is the involvement of bone density which is referred to as metabolic bone disease (MBD), including osteopenia and osteoporosis. Bone alterations in IBDs population appear to have a multifactorial etiology: Decreased physical activity, inflammation-related bone resorption, multiple intestinal resections, dietary malabsorption of minerals and vitamin D deficiency, genetic factors, gut-bone immune signaling interaction, steroid treatment, microbiota and pathogenic micro-organisms interaction, and dietary malabsorption of minerals, that, all together or individually, may contribute to the alteration of bone mineral density. This review aims to summarize the prevalence and pathophysiology of metabolic bone alterations in IBD subjects outlining the main risk factors of bone fragility. We also want to underline the role of the screening and prophylaxis of bone alterations in Crohn's disease and ulcerative colitis patients and the importance of treating appropriately MBD.

Citing Articles

Persistently Elevated C-Reactive Protein Levels and Low Body Mass Index Are Associated with a Lack of Improvement in Bone Mineral Density in Crohn's Disease.

Koifman E, Krasnopolsky M, Ghersin I, Waterman M Nutrients. 2024; 16(17).

PMID: 39275145 PMC: 11396862. DOI: 10.3390/nu16172827.

Identification of neutrophil extracellular traps and crosstalk genes linking inflammatory bowel disease and osteoporosis by integrated bioinformatics analysis and machine learning.

Xu G, Zhang W, Yang J, Sun N, Qu X Sci Rep. 2023; 13(1):23054.

PMID: 38155235 PMC: 10754907. DOI: 10.1038/s41598-023-50488-4.

Signaling pathways associated with bone loss in inflammatory bowel disease.

Palatianou M, Karamanolis G, Tsentidis C, Gourgiotis D, Papaconstantinou I, Vezakis A Ann Gastroenterol. 2023; 36(2):132-140.

PMID: 36864939 PMC: 9932862. DOI: 10.20524/aog.2023.0785.

Pleiotropic Effects of Vitamin D in Patients with Inflammatory Bowel Diseases.

Szymczak-Tomczak A, Ratajczak A, Kaczmarek-Rys M, Hryhorowicz S, Rychter A, Zawada A J Clin Med. 2022; 11(19).

PMID: 36233580 PMC: 9573215. DOI: 10.3390/jcm11195715.

Overweight and abdominal fat are associated with normal bone mineral density in patients with ulcerative colitis.

Lopes M, Lyra A, Rocha R, Coqueiro F, Lima C, de Oliveira C World J Gastrointest Pharmacol Ther. 2022; 13(4):57-66.

PMID: 36051180 PMC: 9297289. DOI: 10.4292/wjgpt.v13.i4.57.

References

Takahashi N, Udagawa N, Suda T . A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun. 1999; 256(3):449-55. DOI: 10.1006/bbrc.1999.0252. View

von Tirpitz C, Pischulti G, Klaus J, Rieber A, Bruckel J, Bohm B . [Pathological bone density in chronic inflammatory bowel diseases--prevalence and risk factors]. Z Gastroenterol. 1999; 37(1):5-12. View

Tsuboi M, Kawakami A, Nakashima T, Matsuoka N, Urayama S, Kawabe Y . Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med. 1999; 134(3):222-31. DOI: 10.1016/s0022-2143(99)90201-9. View

Hofbauer L, Gori F, Riggs B, Lacey D, Dunstan C, Spelsberg T . Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999; 140(10):4382-9. DOI: 10.1210/endo.140.10.7034. View

Scott E, Gaywood I, Scott B . Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut. 2000; 46 Suppl 1:i1-8. PMC: 1766735. DOI: 10.1136/gut.46.suppl_1.i1. View

Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A . Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem. 2000; 275(7):4858-64. DOI: 10.1074/jbc.275.7.4858. View

Schulte C, Dignass A, Goebell H, Roher H, Schulte K . Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000; 119(4):909-20. DOI: 10.1053/gast.2000.18158. View

Arron J, Choi Y . Bone versus immune system. Nature. 2000; 408(6812):535-6. DOI: 10.1038/35046196. View

Kaji K, Katogi R, Azuma Y, Naito A, Inoue J, Kudo A . Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. J Bone Miner Res. 2001; 16(9):1593-9. DOI: 10.1359/jbmr.2001.16.9.1593. View

10.

Nemetz A, Toth M, Garcia-Gonzalez M, Zagoni T, Feher J, Pena A . Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut. 2001; 49(5):644-9. PMC: 1728500. DOI: 10.1136/gut.49.5.644. View

11.

Theill L, Boyle W, Penninger J . RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002; 20:795-823. DOI: 10.1146/annurev.immunol.20.100301.064753. View

12.

Abitbol V, Mary J, Roux C, Soule J, Belaiche J, Dupas J . Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther. 2002; 16(5):919-27. DOI: 10.1046/j.1365-2036.2002.01247.x. View

13.

Best W, Becktel J, SINGLETON J, KERN Jr F . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70(3):439-44. View

14.

Bernstein C, Leslie W, LeBoff M . AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003; 124(3):795-841. DOI: 10.1053/gast.2003.50106. View

15.

TRUELOVE S, Witts L . Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955; 2(4947):1041-8. PMC: 1981500. DOI: 10.1136/bmj.2.4947.1041. View

16.

van Staa T, Laan R, Barton I, Cohen S, Reid D, Cooper C . Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003; 48(11):3224-9. DOI: 10.1002/art.11283. View

17.

Boubaker J, Feki M, Hsairi M, Fekih M, Kaabachi N, Filali A . [Osteoporosis and inflammatory bowel disease: prevalence and risk factors in Tunisian patients]. Gastroenterol Clin Biol. 2003; 27(10):901-7. View

18.

Ashcroft A, Cruickshank S, Croucher P, Perry M, Rollinson S, Lippitt J . Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity. 2003; 19(6):849-61. DOI: 10.1016/s1074-7613(03)00326-1. View

19.

Jahnsen J, Falch J, Mowinckel P, Aadland E . Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol. 2004; 39(2):145-53. DOI: 10.1080/00365520310007873. View

20.

Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M . Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther. 2004; 20(6):607-14. DOI: 10.1111/j.1365-2036.2004.02152.x. View